These new data show that after 12 weeks treatment with darifenacin, people with OAB symptoms are more able to undertake household tasks, socialise, work and travel. They are also less likely to feel depressed, anxious or nervous, as demonstrated by improvements in the King's Health Questionnaire (a questionnaire designed to assess the impact of bladder problems on patient's quality of life).
"OAB symptoms can severely restrict people's lives. People with OAB find urgency - a sudden compelling desire to pass urine, which is difficult to defer - to be particularly bothersome. Less mobile people find this hard to cope with, as they require greater time to reach a toilet. This can cause patients to avoid leaving their home, which severely restricts their lives and can result in social isolation and depression," said Con Kelleher, Consultant in Obstetrics and Gynaecology at Guy's and St Thomas' Hospitals Trust, London, UK. "These new data show that darifenacin significantly improved the quality of life for people with OAB, enabling them to resume everyday activities and lead less restricted lives."
Today's data also highlight darifenacin's tolerability and safety; as central nervous system (CNS) and cardiovascular (CV) safety were comparable to placebo.1 Recent reports provide emerging evidence, however, that current marketed treatments may create CNS problems such as cognitive impairment, due to a blockade of the M1 muscarinic receptor, and somnolence (unnatural drowsiness).3,4,5
Anti-cholinergics are the treatment of choice
'"/>
28-Jun-2004